Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

• Status: Not yet recruiting
• Trial end date: 2024-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

This double-blinded, placebo-control trial clinical trial aims to investigate the effect of IV oxytocin infusion on peri-operative opioid consumption following a minimally invasive hysterectomy under general anesthesia.

patients population will be women who have been scheduled for an elective, minimally invasive hysterectomy at Beth Israel Deaconness Medical Center.

We hypothesize that, compared to a placebo, exposure to intravenous (IV) oxytocin will reduce the amount of opioid consumption for women after a minimally invasive hysterectomy procedure.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beth Israel Deaconess Medical Center
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• women the age of 18-65 years old undergoing elective, minimally invasive hysterectomy under general anesthesia

Exclusion Criteria:

• ASA 4 or greater

• Additional surgical components including but not limited to: minor laparotomy, omentectomy, cystectomy, and lymph node dissection.

• Allergies to any study medication: acetaminophen, ketorolac, hydromorphone, oxycodone, fentanyl, gabapentin, pregabalin.

• Epidural/Regional anesthesia use for intra-operative or post-operative pain.